MCID: HPT019
MIFTS: 59

Hepatic Encephalopathy

Categories: Rare diseases, Liver diseases, Neuronal diseases

Aliases & Classifications for Hepatic Encephalopathy

MalaCards integrated aliases for Hepatic Encephalopathy:

Name: Hepatic Encephalopathy 12 72 49 36 51 14 69
Portal-Systemic Encephalopathy 12
Encephalopathy, Hepatic 49
Hepatoencephalopathy 49

Classifications:



External Ids:

Disease Ontology 12 DOID:13413
ICD10 32 K72
ICD9CM 34 572.2
MeSH 41 D006501
NCIt 46 C79596
KEGG 36 H01506
UMLS 69 C0019151

Summaries for Hepatic Encephalopathy

NIH Rare Diseases : 49 Hepatic encephalopathy is a syndrome observed in some patients with cirrhosis. It is defined as a spectrum of neuropsychiatric abnormalities in patients with liver dysfunction, when other known brain disease has been excluded. Signs and symptoms may be debilitating, and they can begin mildly and gradually, or occur suddenly and severely. They may include personality or mood changes, intellectual impairment, abnormal movements, a depressed level of consciousness, and other symptoms. There are several theories regarding the exact cause, but development of the condition is probably at least partially due to the effect of substances that are toxic to nerve tissue (neurotoxic), which are typically present with liver damage and/or liver disease. Treatment depends upon the severity of mental status changes and upon the certainty of the diagnosis. Last updated: 6/22/2016

MalaCards based summary : Hepatic Encephalopathy, also known as portal-systemic encephalopathy, is related to alcoholic liver cirrhosis and hepatic coma. An important gene associated with Hepatic Encephalopathy is TSPO (Translocator Protein), and among its related pathways/superpathways are Immune response IL-23 signaling pathway and Circadian entrainment. The drugs Metformin and Lactulose have been mentioned in the context of this disorder. Affiliated tissues include liver, brain and testes, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A brain disease that is characterized by loss of brain function, the occurrence of confusion, altered level of consciousness, and coma that results when the liver is unable to remove toxins from the blood.

Wikipedia : 72 Hepatic encephalopathy (HE) is an altered level of consciousness as a result of liver failure. Onset may... more...

Related Diseases for Hepatic Encephalopathy

Diseases related to Hepatic Encephalopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 187)
# Related Disease Score Top Affiliating Genes
1 alcoholic liver cirrhosis 32.2 ALB F2 SLC17A5 TNF
2 hepatic coma 32.0 ALB F2 GPT TSPO
3 liver cirrhosis 31.9 ALB F2 GPT SLC17A5
4 hepatitis 31.2 F2 GPT SLC17A5 TNF
5 alcoholic hepatitis 31.0 ALB F2 GPT IL6 SLC17A5 TNF
6 acute liver failure 30.8 ALB F2 GC GPT SLC17A5 TSPO
7 peritonitis 29.9 ALB F2 IL6 TNF
8 meningitis 29.8 ALB IL6 TNF
9 brain edema 29.7 ALB GLUL IL6 SLC1A2 SLC25A13
10 portal hypertension 29.6 ALB F2 GPT TNF
11 hepatitis b 29.0 ALB F2 GPT SLC17A5 TNF
12 viral hepatitis 28.8 ALB F2 GPT SLC17A5 TNF
13 liver disease 28.7 ALB F2 GPT IL6 SLC17A5 SLC25A13
14 psychotic disorder 28.6 MAOB NOS1 S100B
15 infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovascular malformations 12.3
16 combined oxidative phosphorylation deficiency 1 11.8
17 encephalopathy 11.0
18 3-hydroxyacyl-coa dehydrogenase deficiency 10.9
19 hepatic veno-occlusive disease 10.9
20 hepatorenal syndrome 10.9
21 carnitine palmitoyltransferase i deficiency , muscle 10.9
22 congenital extrahepatic portosystemic shunt 10.9
23 antipyrine metabolism 10.6 ALB F2
24 non-a-e hepatitis 10.6 ALB F2
25 scorpion envenomation 10.5 IL6 TNF
26 fournier gangrene 10.5 ALB F2
27 angioimmunoblastic lymphadenopathy with dysproteinemia 10.5 IL6 TNF
28 critical limb ischemia 10.5 IL6 TNF
29 sudden sensorineural hearing loss 10.4 F2 IL6
30 marburg hemorrhagic fever 10.4 F2 TNF
31 abdominal tuberculosis 10.4 ALB F2
32 streptococcal toxic-shock syndrome 10.4 IL6 TNF
33 null-cell leukemia 10.4 IL6 TNF
34 hemorrhagic fever with renal syndrome 10.4 ALB IL6 TNF
35 keratoconjunctivitis sicca 10.4 ALB IL6 TNF
36 atypical depressive disorder 10.4 MAOA MAOB
37 pyelonephritis 10.4 ALB IL6 TNF
38 typhoid fever 10.4 ALB IL6 TNF
39 appendicitis 10.4 ALB IL6 TNF
40 intermittent claudication 10.4 ALB F2 IL6
41 filariasis 10.4 ALB IL6 TNF
42 gastroenteritis 10.3 ALB IL6 TNF
43 primary bacterial infectious disease 10.3 ALB IL6 TNF
44 intestinal disease 10.3 ALB IL6 TNF
45 hypersensitivity reaction disease 10.3 ALB IL6 TNF
46 end stage renal failure 10.3 ALB IL6 TNF
47 chronic fatigue syndrome 10.3 IL6 MAOA TNF
48 otitis media 10.3 ALB IL6 TNF
49 infective endocarditis 10.3 F2 IL6 TNF
50 respiratory system disease 10.3 ALB IL6 TNF

Comorbidity relations with Hepatic Encephalopathy via Phenotypic Disease Network (PDN): (show all 26)


Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Acute Kidney Failure
Alcohol Abuse Alcoholic Hepatitis
Alcoholic Liver Cirrhosis Chronic Kidney Failure
Decubitus Ulcer Deficiency Anemia
Encephalopathy Esophageal Varix
Heart Disease Hepatitis
Hepatocellular Carcinoma Hepatorenal Syndrome
Hypersplenism Liver Disease
Neutropenia Portal Hypertension
Portal Vein Thrombosis Primary Biliary Cirrhosis
Protein-Energy Malnutrition Respiratory Failure
Schizophreniform Disorder Urea Cycle Disorder

Graphical network of the top 20 diseases related to Hepatic Encephalopathy:



Diseases related to Hepatic Encephalopathy

Symptoms & Phenotypes for Hepatic Encephalopathy

MGI Mouse Phenotypes related to Hepatic Encephalopathy:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.1 F2 GLS GLUL IL6 MAOA MAOB
2 homeostasis/metabolism MP:0005376 10.1 ALB F2 GC GLUL IL6 MAOA
3 liver/biliary system MP:0005370 9.7 ALB GLUL IL6 NOS1 SLC25A13 TNF
4 mortality/aging MP:0010768 9.7 ALB F2 GLS GLUL IL6 NOS1
5 normal MP:0002873 9.23 ALB F2 GLS GLUL NOS1 S100B

Drugs & Therapeutics for Hepatic Encephalopathy

Drugs for Hepatic Encephalopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 232)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4 657-24-9 4091 14219
2
Lactulose Approved Phase 4,Phase 3,Phase 2,Phase 1 4618-18-2 11333
3
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
4
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
5
Rifaximin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 80621-81-4 6436173
6
Magnesium oxide Approved Phase 4 1309-48-4 14792
7
Propranolol Approved, Investigational Phase 4,Phase 3 525-66-6 4946
8
Norfloxacin Approved Phase 4,Phase 3 70458-96-7 4539
9
Insulin Aspart Approved Phase 4 116094-23-6 16132418
10
Midodrine Approved Phase 4 42794-76-3, 133163-28-7 4195
11
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
12
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
13
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 644073 40400
14
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
15
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
16
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
17
Promethazine Approved, Investigational Phase 4 60-87-7 4927
18
Entecavir Approved, Investigational Phase 4,Phase 2 142217-69-4 153941
19
Tolvaptan Approved Phase 4,Phase 3 150683-30-0 216237
20
Tranexamic Acid Approved Phase 4 1197-18-8 5526
21
Ornithine Approved, Nutraceutical Phase 4,Phase 3,Phase 2 70-26-8, 3184-13-2 6262
22
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4 445354
23 Hypoglycemic Agents Phase 4
24 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
25 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
26 Excitatory Amino Acid Agonists Phase 4,Phase 3,Phase 2
27 Excitatory Amino Acids Phase 4,Phase 3,Phase 2
28 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
29 N-Methylaspartate Phase 4,Phase 3,Phase 2
30 Adjuvants, Anesthesia Phase 4
31 Anesthetics Phase 4,Phase 2
32 Anesthetics, General Phase 4
33 Anesthetics, Intravenous Phase 4
34 Anti-Anxiety Agents Phase 4
35 Central Nervous System Depressants Phase 4,Phase 2
36 GABA Agents Phase 4,Phase 1,Phase 2
37 GABA Modulators Phase 4,Phase 1,Phase 2
38 Hypnotics and Sedatives Phase 4,Phase 2
39 Psychotropic Drugs Phase 4
40 Tranquilizing Agents Phase 4
41 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
42 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
43 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
44 rifamycin SV Phase 4,Phase 3,Phase 2,Phase 1
45 Rifamycins Phase 4,Phase 3,Phase 2,Phase 1
46 Antacids Phase 4
47 Anti-Ulcer Agents Phase 4
48 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3
49 Adrenergic Agents Phase 4,Phase 3,Phase 2
50 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 218)

# Name Status NCT ID Phase Drugs
1 Metformin Experience on Minimal Hepatic Encephalopathy Unknown status NCT02470546 Phase 4 Metformin;Placebo
2 Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis Unknown status NCT01175538 Phase 4 Lactulose;Lactulose
3 Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis Unknown status NCT01178372 Phase 4 Lactulose;Probiotics(VSL#3)
4 Efficacy of Combined Oral L-Ornithine-L-Aspartate and Lactulose in Patients With Hepatic Encephalopathy Unknown status NCT00740142 Phase 4 L-ornithine-L-aspartate and lactulose;placebo and lactulose
5 Trial Comparing Sedation for Endoscopy With Propofol Versus Midazolam in Cirrhotics Unknown status NCT01356121 Phase 4 Propofol;Midazolam
6 Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Minimal Encephalopathy Unknown status NCT00896831 Phase 4 L-ornithine-L-aspartate;placebo
7 Rifaximin Versus Lactulose in Renal Failure Unknown status NCT00748904 Phase 4 Rifaximin;Lactulose
8 Magnesium in Liver Cirrhosis Unknown status NCT01894867 Phase 4
9 Lactulose, L-ornithine L-aspartate, or Rifaximin Versus Placebo for Preventing Hepatic Encephalopathy in Variceal Bleeding Completed NCT02158182 Phase 4 Lactulose;L-ornithine L-aspartate;Rifaximin;Placebo
10 Effects of Proteins in Patients With Cirrhosis and Prior Hepatic Encephalopathy Completed NCT00955500 Phase 4
11 Post Transjugular Intrahepatic Portosystemic Shunt (Tips) Albumine Infusion to Prevent Hepatic Encephalopathy Completed NCT01559519 Phase 4 Albumin
12 Brain Muscle Axis During Treatment of Hepatic Encephalopathy With L-ornithine L-aspartate Completed NCT01847651 Phase 4 LOLA or placebo
13 Efficacy of L-Ornithine L-Aspartate in Acute Hepatic Encephalopathy. Completed NCT01041755 Phase 4 L-ornithine-L-aspartate;Lactose
14 Effect of Lactulose on Minimal Hepatic Encephalopathy and Health-Related Quality of Life Completed NCT00375375 Phase 4 Lactulose
15 Randomised Controlled Trial of Mechanistic Effects of Rifaximin in Cirrhosis and Chronic Hepatic Encephalopathy Completed NCT02019784 Phase 4 Rifaximin-α;Placebo Oral Tablet
16 Efficacy of Albumin for Acute Encephalopathy in Patients With Cirrhosis Completed NCT00886925 Phase 4 Albumin;Sodium chloride 0.9%
17 The Safety/Efficacy Of Rifaximin With/Without Lactulose In Subjects With A History Of Recurrent Hepatic Encephalopathy Completed NCT01842581 Phase 4 Rifaximin;Rifaximin and Lactulose
18 L-ornithine L-aspartate in Overt Hepatic Encephalopathy Completed NCT01722578 Phase 4 L-ornithine L-aspartate;Placebo
19 Branched Chain Aminoacid Supplementation in Patients With Liver Cirrhosis Completed NCT02023229 Phase 4
20 Effect of Midodrine and Albumine in the Prevention of Complications in Cirrhotic Patients Awaiting Liver Transplantation Completed NCT00839358 Phase 4 albumin;Midodrine;Placebo
21 Study on B-blockers to Prevent Decompensation of Cirrhosis With HTPortal Completed NCT01059396 Phase 4 propranolol;carvedilol;placebo
22 Norfloxacin Versus Ciprofloxacin for Spontaneous Bacterial Peritonitis (SBP) Prevention Completed NCT01542801 Phase 4 Norfloxacin;ciprofloxacin
23 Effects on Plasma Exchange on Functional Capacity of Serum Albumin, Circulatory Dysfunction, Renal and Cerebral Function in Cirrhotic Patients With "Acute-on-chronic Liver Failure" Completed NCT01201720 Phase 4
24 Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects Completed NCT01846455 Phase 4 2.0mg Buprenorphine/0.5mg Naloxone;Promethazine
25 Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy Recruiting NCT01846663 Phase 4 Placebo;Rifaximin
26 Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic Encephalopathy Recruiting NCT02401490 Phase 4 Human albumin;Placebo
27 PEG (Polyethylene Glycol)Versus Lactulose For Treatment Of Overt Hepatic Encephalopathy Recruiting NCT03100513 Phase 4 Lactulose;Polyethylene Glycol
28 Early Precise Diagnosis and Intervention of CPT Based on a Noninvasive 3D-vHPS Recruiting NCT02925975 Phase 4 Carvedilol
29 Effect of Entecavir Treatment on Regression and Disease Outcome in HBV-induced Liver Fibrosis and Cirrhosis Patients Recruiting NCT02849132 Phase 4 Entecavir
30 Ramelteon for Treatment of Insomnia in Cirrhosis Recruiting NCT03091738 Phase 4 Ramelteon Pill
31 Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography Recruiting NCT02757170 Phase 4
32 Rifaximin Reduces the Complications of Decompensated Cirrhosis: a Randomized Controlled Trial Recruiting NCT02190357 Phase 4 Rifaximin
33 The Effect of Branched-chain Amino Acid on the Improvement of Serum Albumin Level in Cirrhotic Patients With Ascites Recruiting NCT02755701 Phase 4 Branched-chain Amino Acid;Placebo
34 Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy Not yet recruiting NCT03077217 Phase 4 Rifaximin
35 Efficacity and Safety of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding Not yet recruiting NCT03023189 Phase 4 Tranexamic acid;Placebo
36 Prompt Or Watchful Monitoring for Hepatitis B Virus Related Hepatocellular Carcinoma Without Elevated viRal Load Not yet recruiting NCT02308319 Phase 4 Tenofovir disoproxil fumarate
37 Quality of Life and Nutritional Improvements in Cirrhotic Patients Terminated NCT01842113 Phase 4 Rifaximin;Lactulose;Lactulose Placebo;Rifaximin Placebo
38 Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia Terminated NCT01890694 Phase 4 Tolvaptan;Placebo
39 Effect of Intrathoracic Pressure Regulation on Traumatic Brain Injury Terminated NCT01824589 Phase 4
40 Impact of an Antibiotic (Rifaximin) on Liver Scarring in HIV-Infected Patients With Liver Disease Withdrawn NCT01654939 Phase 4 Rifaximin
41 ETOS: Minimal Hepatic Encephalopathy in Childhood and Young Adult: epidemiOlogical Study and Pilot Interventional Study Unknown status NCT01798329 Phase 3
42 RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial Unknown status NCT00364689 Phase 3 Rifaximin alone, Rifaximin combined with Lactulose
43 Lactulose for the Prevention of Hepatic Encephalopathy in Cirrhotic Patients With Upper Gastrointestinal Hemorrhage Unknown status NCT00553423 Phase 3 Lactulose;Placebo
44 To Study the Effect of Nonselective Beta Blockers in Advanced Stage Liver Disease With Ascites Unknown status NCT02649335 Phase 3 Propranolol
45 Probiotics for Portal Hypertension Unknown status NCT01134692 Phase 3 Propranolol, Norfloxacin, VSL#3
46 HR Versus RFA for Early Stage HCC Unknown status NCT02169765 Phase 3
47 Secondary Prophylaxis of Hepatic Encephalopathy With a Probiotic Preparation Completed NCT01110447 Phase 2, Phase 3 VSL#3
48 Efficacy of L-Ornithine-L-Aspartate in Cirrhotics With Hepatic Encephalopathy Completed NCT00433368 Phase 3 L-Ornithine L-Aspartate
49 A 6-month Efficacy, Safety and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy Completed NCT00298038 Phase 3 Rifaximin
50 Safety Study for Patients With a History of Hepatic Encephalopathy Completed NCT00686920 Phase 3 rifaximin

Search NIH Clinical Center for Hepatic Encephalopathy

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Genetic Tests for Hepatic Encephalopathy

Anatomical Context for Hepatic Encephalopathy

MalaCards organs/tissues related to Hepatic Encephalopathy:

38
Liver, Brain, Testes, Cortex, Small Intestine, Monocytes, Bone Marrow

Publications for Hepatic Encephalopathy

Articles related to Hepatic Encephalopathy:

(show top 50) (show all 788)
# Title Authors Year
1
Prediction of Hepatic Encephalopathy: Why disregard well known risk factors? ( 29377250 )
2018
2
Improving Quality of Care for People with Hepatic Encephalopathy. ( 29411992 )
2018
3
Baicalin reverses the impairment of synaptogenesis induced by dopamine burden via the stimulation of GABA<sub>A</sub>R-TrkB interaction in minimal hepatic encephalopathy. ( 29404643 )
2018
4
Disrupted Brain Intrinsic Networks and Executive Dysfunction in Cirrhotic Patients without Overt Hepatic Encephalopathy. ( 29422882 )
2018
5
Effect of probiotic treatment on cirrhotic patients with minimal hepatic encephalopathy: A meta-analysis. ( 29428113 )
2018
6
EDITORIAL that refers to article 'Treating hepatic encephalopathy in cirrhotic patients admitted to ICU with sodium phenylbutyrate: a preliminary study'. ( 29430750 )
2018
7
Is Lactulose Plus Rifaximin Better than Lactulose Alone in the Management of Hepatic Encephalopathy? ( 29394969 )
2018
8
Effect of Post-Traumatic Stress Disorder on Cognitive Function and Covert Hepatic Encephalopathy Diagnosis in Cirrhotic Veterans. ( 29313245 )
2018
9
Effect of sirolimus on liver cirrhosis and hepatic encephalopathy of common bile duct-ligated rats. ( 29444470 )
2018
10
Hepatic encephalopathy: causes and health-related burden. ( 29411993 )
2018
11
Diagnosis and management of hepatic encephalopathy. ( 29411990 )
2018
12
Multimodal MR imaging in hepatic encephalopathy: state of the art. ( 29374342 )
2018
13
Effects of Alcohol on the Brain in Cirrhosis: Beyond Hepatic Encephalopathy. ( 29417604 )
2018
14
Osmotic Shifts, Cerebral Edema, and Neurologic Deterioration in Severe Hepatic Encephalopathy. ( 29341965 )
2018
15
Re: Prediction of Hepatic Encephalopathy: why disregard well known risk factors? ( 29365345 )
2018
16
Stroop Test Validation to Screen for Minimal Hepatic Encephalopathy in Pediatric Extrahepatic Portal Venous Obstruction. ( 29373442 )
2018
17
Impact of intestinal mannitol on hyperammonemia, oxidative stress and severity of hepatic encephalopathy in the ED. ( 29352675 )
2018
18
Covert hepatic encephalopathy leads to distinct alterations in the emotional state, independently of MELD-Score. ( 29341039 )
2018
19
Duration of the acute hepatic encephalopathy episode determines survival in cirrhotic patients. ( 29383024 )
2018
20
Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy. ( 28799305 )
2017
21
Performance characterization of a novel electronic number connection test to detect minimal hepatic encephalopathy in cirrhotic patients. ( 28092641 )
2017
22
Effects on cognitive function of propofol medium and long chain lipid emulsion in patients with hepatic encephalopathy. ( 28884566 )
2017
23
Covert Hepatic Encephalopathy: Can My Patient Drive? ( 28027071 )
2017
24
Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy. ( 28836723 )
2017
25
Hepatic encephalopathy: a critical current review. ( 28770516 )
2017
26
Concurrent assessment of calpain and caspase3 activities in brains of mice with acetaminophen-induced acute hepatic encephalopathy. ( 28828727 )
2017
27
Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity. ( 29307995 )
2017
28
Overt Hepatic Encephalopathy impairs learning on the Encephalapp Stroop which is Reversible after Liver Transplant. ( 28885772 )
2017
29
The Effects of Probiotics and Symbiotics on Risk Factors for Hepatic Encephalopathy: A Systematic Review. ( 28059938 )
2017
30
Dopamine Burden Induced the Inactivation of Sonic Hedgehog Signaling to Cognitive Decline in Minimal Hepatic Encephalopathy. ( 28840059 )
2017
31
Nitric oxide mediates effects of acute, not chronic, naltrexone on LPS-induced hepatic encephalopathy in cirrhotic rats. ( 28044452 )
2017
32
Hepatic Encephalopathy. ( 28076712 )
2017
33
Brain Microstructural Abnormalities in Patients With Cirrhosis Without Overt Hepatic Encephalopathy: A Voxel-Based Diffusion Kurtosis Imaging Study. ( 28813200 )
2017
34
Hepatic Encephalopathy. ( 28079344 )
2017
35
Ammonia Levels and Hepatic Encephalopathy in Patients with Known Chronic Liver Disease. ( 28786433 )
2017
36
A Observational cohort study of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt (TIPS). ( 28051803 )
2017
37
Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy. ( 28796283 )
2017
38
Neuron-derived CCL2 contributes to microglia activation and neurological decline in hepatic encephalopathy. ( 28870240 )
2017
39
Sleep disturbances in patients of liver cirrhosis with minimal hepatic encephalopathy before and after lactulose therapy. ( 28070704 )
2017
40
Hepatic Encephalopathy. ( 28069286 )
2017
41
Fecal microbiota transplantation for treating recurrent hepatic encephalopathy: Ready for clinical application? ( 28936973 )
2017
42
Regional cerebral blood flow assessed by single photon emission computed tomography (SPECT) in dogs with congenital portosystemic shunt and hepatic encephalopathy. ( 28190492 )
2017
43
Validation of a Paper and Pencil Test Battery for the Diagnosis of Minimal Hepatic Encephalopathy in Korea. ( 28776344 )
2017
44
Hepatic Encephalopathy. ( 28079343 )
2017
45
A Minimal hepatic encephalopathy in cirrhosis- how long to treat? ( 28051800 )
2017
46
Refractory hepatic encephalopathy in a patient with hypothyroidism: Another element in ammonia metabolism. ( 28811719 )
2017
47
Lactulose enemas in the treatment of hepatic encephalopathy. Do we help or harm? ( 28929776 )
2017
48
An educational tool for the prophylaxis of hepatic encephalopathy. ( 28944074 )
2017
49
Electro-Radiological Observations of Grade III/IV Hepatic Encephalopathy Patients with Seizures. ( 28791561 )
2017
50
Shunt-preserving disconnection of the portal to systemic circulation in patients with hepatic encephalopathy. ( 28791885 )
2017

Variations for Hepatic Encephalopathy

Expression for Hepatic Encephalopathy

LifeMap Discovery
Genes differentially expressed in tissues of Hepatic Encephalopathy patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 PSPH phosphoserine phosphatase Brain - 4.35 0.000
Search GEO for disease gene expression data for Hepatic Encephalopathy.

Pathways for Hepatic Encephalopathy

Pathways related to Hepatic Encephalopathy according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.38 F2 IL6 NOS1 TNF
2
Show member pathways
12.1 GLS GLUL MAOA MAOB NOS1 SLC1A2
3
Show member pathways
12.04 ALB F2 IL6 TNF
4 11.86 ALB S100B TSPO
5 11.81 IL6 NOS1 TNF
6
Show member pathways
11.77 NOS1 SLC1A2 TNF
7 11.76 IL6 MAOA TNF
8 11.59 GLS GLUL MAOA
9
Show member pathways
11.3 MAOA MAOB NOS1
10
Show member pathways
11.13 MAOA NOS1 TNF
11
Show member pathways
11.06 GLS GLUL GPT
12 10.88 GLS GLUL GPT
13 10.85 IL6 TNF
14
Show member pathways
10.69 MAOA MAOB
15 10.64 MAOA MAOB
16
Show member pathways
10.59 MAOA MAOB
17
Show member pathways
10.34 GLUL SLC1A2
18
Show member pathways
10.34 GLS GLUL GPT NOS1

GO Terms for Hepatic Encephalopathy

Cellular components related to Hepatic Encephalopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.5 ALB F2 GC GPT IL6 S100B
2 mitochondrion GO:0005739 9.17 GLS GLUL MAOA MAOB NOS1 SLC25A13

Biological processes related to Hepatic Encephalopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.76 IL6 S100B TNF TSPO
2 cellular response to lipopolysaccharide GO:0071222 9.65 IL6 TNF TSPO
3 L-glutamate transmembrane transport GO:0089711 9.43 SLC1A2 SLC25A13
4 L-glutamate transport GO:0015813 9.4 SLC1A2 SLC25A13
5 neurotransmitter catabolic process GO:0042135 9.37 MAOA MAOB
6 response to glucocorticoid GO:0051384 9.33 IL6 S100B TNF
7 negative regulation of lipid storage GO:0010888 9.32 IL6 TNF
8 dopamine catabolic process GO:0042420 9.26 MAOA MAOB
9 positive regulation of STAT protein import into nucleus GO:2000366 8.96 F2 IL6
10 cellular amino acid biosynthetic process GO:0008652 8.8 GLS GLUL GPT

Molecular functions related to Hepatic Encephalopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 L-glutamate transmembrane transporter activity GO:0005313 8.96 SLC1A2 SLC25A13
2 primary amine oxidase activity GO:0008131 8.62 MAOA MAOB

Sources for Hepatic Encephalopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....